MGA and non-small cell lung carcinoma: According to Kaplan–Meier survival analysis results, MGA mutation was significantly associated with a better immunotherapeutic outcome in the NSCLC cohorts (mOS = 16 months vs. 9.5 months, log-rank test, p = 0.028; Figure 2A).